Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Completed · Phase 2

Conditions studied: Triple Negative Breast Cancer

In brief

This is a phase II study randomizing patients with stage I with T1 \> 1.5 cm, stage II or III triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel. The study is designed to evaluate the ability of the Homologous Recombination Deficiency (HRD) assay to predict pathologic response to preoperative chemotherapy.

Key facts

Study ID
NCT01982448
Run by
Dana-Farber Cancer Institute
People needed
147
Starts
2014-04-01
Expected to finish
2020-08-01
Last updated by the study team
2025-09-30

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.